Cargando…

Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union

Legislation for expedited‐approval pathways and programmes for drugs, biologics or medical devices has been enacted for rapid commercialization of innovative products in the United States of America (USA) and the European Union (EU). However, less innovative products are increasingly benefitting fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jokura, Yoji, Yano, Kazuo, Yamato, Masayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836905/ https://www.ncbi.nlm.nih.gov/pubmed/28211195 http://dx.doi.org/10.1002/term.2428

Ejemplares similares

Expedited approval system for regenerative medicine products – Is it unusual?
por: Yano, Kazuo, et al.
Publicado: (2016)

Bayesian statistics and clinical trial designs for human cells and tissue products for regulatory approval
por: Jokura, Yoji, et al.
Publicado: (2016)

Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan
por: Yano, Kazuo, et al.
Publicado: (2014)

Compassionate use of drugs and medical devices in the United States, the European Union and Japan
por: Tsuyuki, Kenichiro, et al.
Publicado: (2016)

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
por: Hwang, Thomas J., et al.
Publicado: (2022)

Compassionate use and hospital exemption for regenerative medicine: Something wrong to apply the program for patients in a real world
por: Yano, Kazuo, et al.
Publicado: (2018)

Predictors of orphan drug approval in the European Union
por: Heemstra, Harald E., et al.
Publicado: (2008)

Approval and Certification of Ophthalmic AI Devices in the European Union
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine
por: Kantor, Ariel, et al.
Publicado: (2021)

Cell-based medicinal products approved in the European Union: current evidence and perspectives
por: Bellino, Stefania, et al.
Publicado: (2023)

Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera
por: Watanabe, Natsumi, et al.
Publicado: (2015)

Expedited regulatory product approval in the time of COVID-19
por: Novack, Gary D.
Publicado: (2022)

Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation
por: ‘t Hoen, Ellen F. M., et al.
Publicado: (2017)

Preface of the special issue: Regenerative medicine of the digestive tract
por: Yamato, Masayuki, et al.
Publicado: (2020)

Risk‐based approach in the revised European Union drinking water legislation: Opportunities for bioanalytical tools
por: Dingemans, Milou ML, et al.
Publicado: (2018)

How the European Union legislations are tackling the burden of diabetes mellitus: A legal surveillance study
por: Mahrouseh, Nour, et al.
Publicado: (2022)

European Union Legislation for the Welfare of Animals Used for Scientific Purposes: Areas Identified for Further Discussion
por: Marinou, Katerina A., et al.
Publicado: (2023)

Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study
por: Larochelle, Matthieu, et al.
Publicado: (2017)

Industrial Relations, Trade Unions, and Labour Legislation
por: Sinha, P
Publicado: (2012)

FDA expedited approval and implications for rational formulary and health plan design
por: Ferries, Erin A, et al.
Publicado: (2021)

The Evolution of Legislation in the Field of Medically Assisted Reproduction and Embryo Stem Cell Research in European Union Members
por: Busardò, Francesco Paolo, et al.
Publicado: (2014)

Navigating the maze of requirements for obtaining approval of non-interventional studies (NIS) in the European Union
por: Ramirez, Isabelle
Publicado: (2015)

Engineered Microorganisms for the Production of Food Additives Approved by the European Union—A Systematic Analysis
por: Kallscheuer, Nicolai
Publicado: (2018)

Distinct fibroblast progenitor subpopulation expedites regenerative mucosal healing by immunomodulation
por: Ko, Kang I., et al.
Publicado: (2022)

The impact of the treaty basis on health policy legislation in the European Union: A case study on the tobacco advertising directive
por: Boessen, Sandra, et al.
Publicado: (2008)

Smoking Behaviour, Involuntary Smoking, Attitudes towards Smoke-Free Legislations, and Tobacco Control Activities in the European Union
por: Martínez-Sánchez, Jose M., et al.
Publicado: (2010)

Acetylsalicylic acid as a potential pediatric health hazard: legislative aspects concerning accidental intoxications in the European Union
por: Mund, Menen E., et al.
Publicado: (2016)

Social diversity and access to healthcare in Europe: how does European Union’s legislation prevent from discrimination in healthcare?
por: Orzechowski, Marcin, et al.
Publicado: (2020)

RNA-based drugs and regulation: Toward a necessary evolution of the definitions issued from the European union legislation
por: Guerriaud, Mathieu, et al.
Publicado: (2022)

3.G. Round table: European Union policies: the basis for EU legislation and the case of the EU HTA regulation
Publicado: (2023)

Regulatory Pathways Supporting Expedited Drug Development and Approval in ICH Member Countries
por: Franco, Pedro, et al.
Publicado: (2022)

The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018
por: Schuster Bruce, Catherine, et al.
Publicado: (2019)

Affordability of medicines in the European Union
por: Zaprutko, Tomasz, et al.
Publicado: (2017)

Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan
por: Nagai, Sumimasa
Publicado: (2019)

Expediting COVID-19 vaccination increases QALYs and saves costs in the USA
Publicado: (2021)

Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review
por: Anker, Markus S., et al.
Publicado: (2019)

Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?
por: Shepshelovich, Daniel, et al.
Publicado: (2018)

Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics
por: Wong, Alissa K., et al.
Publicado: (2023)

COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients
por: Bellino, Stefania
Publicado: (2022)

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
por: Hwang, Thomas J, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ggecd0dgdr4o87m6rcknh7526s